within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD16_MetforminAndCanagliflozin;
model MetforminAndCanagliflozin 
   extends Pharmacolibrary.Drugs.ATC.A.A10BD16;

  annotation(Documentation(
    info ="<html><body><p>Metformin and canagliflozin is a fixed-dose combination medication used for the treatment of type 2 diabetes mellitus in adults. Metformin is a biguanide antihyperglycemic agent primarily used to improve glycemic control by decreasing hepatic glucose production and increasing insulin sensitivity, while canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidney, resulting in increased urinary glucose excretion. This combination is currently approved and marketed for medical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for average healthy adults, as direct pharmacokinetic parameterization of the fixed-dose combination is not available in publication. Parameters for each component are approximated from studies of individual drugs. Estimated for oral administration of metformin (1000 mg) and canagliflozin (300 mg).</p><h4>References</h4><ol><li><p>Devineni, D, et al., &amp; Usiskin, K (2015). Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants. <i>Clinical pharmacology in drug development</i> 4(3) 226–236. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.166&quot;>10.1002/cpdd.166</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27140803/&quot;>https://pubmed.ncbi.nlm.nih.gov/27140803</a></p></li><li><p>Donnan, K, &amp; Segar, L (2019). SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. <i>European journal of pharmacology</i> 846 23–29. DOI:<a href=&quot;https://doi.org/10.1016/j.ejphar.2019.01.002&quot;>10.1016/j.ejphar.2019.01.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30639796/&quot;>https://pubmed.ncbi.nlm.nih.gov/30639796</a></p></li><li><p>Murphy, J, et al., &amp; Devineni, D (2015). Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants. <i>International journal of clinical pharmacology and therapeutics</i> 53(3) 256–264. DOI:<a href=&quot;https://doi.org/10.5414/CP202233&quot;>10.5414/CP202233</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25546166/&quot;>https://pubmed.ncbi.nlm.nih.gov/25546166</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end MetforminAndCanagliflozin;
